LAPTM4B and breast carcinoma: In particular, the relation of VEGF and survivin protein levels with the expression of LAPTM4B indicates that they could have clinical potential as promising prognostic markers to identify individuals with poor outcomes and may be regarded as therapeutic targets for breast cancer.